234 related articles for article (PubMed ID: 28611108)
1. Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor.
Zeng S; Seifert AM; Zhang JQ; Cavnar MJ; Kim TS; Balachandran VP; Santamaria-Barria JA; Cohen NA; Beckman MJ; Medina BD; Rossi F; Crawley MH; Loo JK; Maltbaek JH; Besmer P; Antonescu CR; DeMatteo RP
Mol Cancer Ther; 2017 Sep; 16(9):1954-1966. PubMed ID: 28611108
[TBL] [Abstract][Full Text] [Related]
2. Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.
Zook P; Pathak HB; Belinsky MG; Gersz L; Devarajan K; Zhou Y; Godwin AK; von Mehren M; Rink L
Clin Cancer Res; 2017 Jan; 23(1):171-180. PubMed ID: 27370604
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.
Gebreyohannes YK; Schöffski P; Van Looy T; Wellens J; Vreys L; Cornillie J; Vanleeuw U; Aftab DT; Debiec-Rychter M; Sciot R; Wozniak A
Mol Cancer Ther; 2016 Dec; 15(12):2845-2852. PubMed ID: 27777285
[TBL] [Abstract][Full Text] [Related]
4. FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.
Li F; Huynh H; Li X; Ruddy DA; Wang Y; Ong R; Chow P; Qiu S; Tam A; Rakiec DP; Schlegel R; Monahan JE; Huang A
Cancer Discov; 2015 Apr; 5(4):438-51. PubMed ID: 25673643
[TBL] [Abstract][Full Text] [Related]
5. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
[TBL] [Abstract][Full Text] [Related]
6. E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor.
García-Valverde A; Rosell J; Sayols S; Gómez-Peregrina D; Pilco-Janeta DF; Olivares-Rivas I; de Álava E; Maurel J; Rubió-Casadevall J; Esteve A; Gut M; Valverde C; Barretina J; Carles J; Demetri GD; Fletcher JA; Arribas J; Serrano C
Oncogene; 2021 Dec; 40(48):6614-6626. PubMed ID: 34621020
[TBL] [Abstract][Full Text] [Related]
7. Ethyl-2-amino-pyrrole-3-carboxylates are active against imatinib-resistant gastrointestinal stromal tumors in vitro and in vivo.
Boichuk S; Galembikova A; Dunaev P; Micheeva E; Novikova M; Khromova N; Kopnin P
Anticancer Drugs; 2019 Jun; 30(5):475-484. PubMed ID: 30986804
[TBL] [Abstract][Full Text] [Related]
8. ETV4 collaborates with Wnt/β-catenin signaling to alter cell cycle activity and promote tumor aggressiveness in gastrointestinal stromal tumor.
Zeng S; Seifert AM; Zhang JQ; Kim TS; Bowler TG; Cavnar MJ; Medina BD; Vitiello GA; Rossi F; Loo JK; Param NJ; DeMatteo RP
Oncotarget; 2017 Dec; 8(69):114195-114209. PubMed ID: 29371979
[TBL] [Abstract][Full Text] [Related]
9. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
[TBL] [Abstract][Full Text] [Related]
10. Integrated Screens Identify CDK1 as a Therapeutic Target in Advanced Gastrointestinal Stromal Tumors.
Lu X; Pang Y; Cao H; Liu X; Tu L; Shen Y; Jia X; Lee JC; Wang Y
Cancer Res; 2021 May; 81(9):2481-2494. PubMed ID: 33727226
[TBL] [Abstract][Full Text] [Related]
11. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
12. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor.
Vitiello GA; Medina BD; Zeng S; Bowler TG; Zhang JQ; Loo JK; Param NJ; Liu M; Moral AJ; Zhao JN; Rossi F; Antonescu CR; Balachandran VP; Cross JR; DeMatteo RP
Clin Cancer Res; 2018 Feb; 24(4):972-984. PubMed ID: 29246941
[No Abstract] [Full Text] [Related]
15. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
[TBL] [Abstract][Full Text] [Related]
16. "Wnt/β-Catenin in GIST"-Letter.
Bertucci F; Finetti P; De Nonneville A; Birnbaum D
Mol Cancer Ther; 2018 Jan; 17(1):327-328. PubMed ID: 29295963
[TBL] [Abstract][Full Text] [Related]
17. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
[TBL] [Abstract][Full Text] [Related]
18. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells.
Thao le B; Vu HA; Yasuda K; Taniguchi S; Yagasaki F; Taguchi T; Watanabe T; Sato Y
Cancer Biol Ther; 2009 Apr; 8(8):683-8. PubMed ID: 19417561
[TBL] [Abstract][Full Text] [Related]
19. SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling.
Sugase T; Takahashi T; Serada S; Fujimoto M; Ohkawara T; Hiramatsu K; Nishida T; Hirota S; Saito Y; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Hanasaki K; Kishimoto T; Mori M; Doki Y; Naka T
Gastric Cancer; 2018 Nov; 21(6):968-976. PubMed ID: 29623544
[TBL] [Abstract][Full Text] [Related]
20. Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells.
Rausch JL; Ali AA; Lee DM; Gebreyohannes YK; Mehalek KR; Agha A; Patil SS; Tolstov Y; Wellens J; Dhillon HS; Makielski KR; Debiec-Rychter M; Schöffski P; Wozniak A; Duensing A
Sci Rep; 2020 Mar; 10(1):5178. PubMed ID: 32198455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]